What's Happening?
Takeda has announced that its TYK2 inhibitor, zasocitinib, has demonstrated superior efficacy compared to Bristol Myers Squibb's (BMS) Sotyktu in a head-to-head study for treating moderate-to-severe plaque psoriasis. The LATITUDE Atlas study revealed
that zasocitinib achieved a PASI 100 response, indicating complete skin clearance, in 35% of patients at week 16, which is more than 2.5 times the response rate of Sotyktu. The study also showed that zasocitinib outperformed Sotyktu on all key secondary endpoints, including the PASI 90 response on the Static Physician's Global Assessment scale. The drug's efficacy was achieved with once-daily dosing, similar to Sotyktu, but with full TYK2 inhibition over 24 hours. Lead investigator Linda Stein Gold highlighted the clinically meaningful differences between the two oral treatments, suggesting that zasocitinib could transform expectations for oral therapies in plaque psoriasis.
Why It's Important?
The results of the LATITUDE Atlas study are significant as they position zasocitinib as a potentially more effective treatment option for patients with moderate-to-severe plaque psoriasis. This could lead to a shift in the market dynamics, challenging BMS's Sotyktu, which had blockbuster expectations but has seen slow sales growth. The superior efficacy of zasocitinib may influence prescribing practices and patient preferences, potentially increasing Takeda's market share in the psoriasis treatment landscape. Additionally, the success of zasocitinib could bolster Takeda's portfolio, as the drug is also being explored for other inflammatory conditions, potentially expanding its therapeutic applications and revenue streams.
What's Next?
Takeda plans to file for regulatory approval of zasocitinib starting this fiscal year, which could lead to its availability as a treatment option for plaque psoriasis and possibly other inflammatory conditions. The company is also exploring the drug's potential in treating psoriatic arthritis, Crohn's disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa. As Takeda moves forward with its approval process, BMS may need to strategize on how to enhance Sotyktu's market performance, possibly by expanding its indications or improving its efficacy. The competitive landscape in psoriasis treatment is likely to intensify, with both companies seeking to capture a larger share of the market.
